ANSWER: C

Rationale:

This patient has developed acute hyperkalemia and AKI through convergent pharmacological mechanisms from three agents acting simultaneously on renal potassium and GFR regulation. Lisinopril, an ACE inhibitor, reduces angiotensin II-driven aldosterone production from the adrenal cortex, lowering aldosterone-mediated potassium excretion in the collecting duct — this is the RAAS-suppression component of his baseline potassium of 4.8 mEq/L. Spironolactone competitively blocks aldosterone at the MR in collecting duct principal cells, directly suppressing ENaC and ROMK transcription and reducing potassium secretion — adding a second, mechanistically distinct potassium-retaining effect on top of the ACE inhibitor. Ibuprofen inhibits cyclooxygenase (COX)-mediated prostaglandin E2 (PGE2) synthesis; PGE2 normally maintains afferent arteriolar tone in states of reduced perfusion pressure. With PGE2 inhibited, afferent arteriolar vasoconstriction reduces GFR acutely, impairing renal potassium excretion through reduced tubular flow in addition to the existing MR blockade and RAAS suppression. In a patient with CKD3b whose renal reserve is already limited, this three-way convergence — ACE-I + MR antagonist + NSAID — has produced the acute presentation. Both spironolactone (the dominant potassium-retaining MR blocker) and ibuprofen (the precipitant of AKI and reduced tubular potassium excretion) should be held immediately. Lisinopril dose reduction can be considered after acute stabilization.

• Option A: Option A is incorrect: lisinopril alone does not account for the acute deterioration; the patient was stable on lisinopril for 14 months, and the acute change was precipitated by ibuprofen adding a GFR-reducing mechanism on top of the existing combination. Holding only lisinopril while continuing spironolactone and ibuprofen does not address the MR antagonist's direct potassium-retaining effect or the NSAID's afferent arteriolar vasoconstriction.
• Option B: Option B is incorrect: furosemide is not contributing to the hyperkalemia or AKI in this euvolemic patient; loop diuretics promote potassium excretion (kaliuresis) rather than retention, and holding furosemide would worsen rather than improve potassium management.
• Option D: Option D is incorrect: ibuprofen alone cannot fully explain the degree of hyperkalemia — the patient was on a substrate of dual RAAS blockade (ACE-I + MR antagonist) that had already raised his baseline potassium to 4.8 mEq/L; ibuprofen was the precipitant but not the sole cause, and the MR antagonist must also be held to adequately reduce the potassium load.
• Option E: Option E is incorrect: continuing all medications while adding sodium polystyrene sulfonate is an insufficient acute response to a potassium of 5.9 mEq/L with concurrent AKI; at this potassium level in a patient with cardiac disease and CKD, the precipitating agents must be removed, not supplemented with a binding resin.

ANSWER: A

Rationale:

Spironolactone's endocrine adverse effects are not sex-limited. In men, androgen receptor blockade produces gynecomastia and erectile dysfunction; in women, progesterone and androgen receptor cross-reactivity produces breast tenderness, mastalgia, and menstrual irregularities including oligomenorrhea and amenorrhea. These are well-documented, dose-dependent effects of spironolactone's lack of receptor selectivity that affect both sexes. Eplerenone, with approximately 40-fold lower affinity for androgen and progesterone receptors than spironolactone, substantially reduces but does not eliminate these adverse effects. With her eGFR of 58 mL/min/1.73 m² and potassium of 4.3 mEq/L, she is an appropriate candidate for eplerenone substitution. While eplerenone's outcomes trial evidence base is in HFrEF (EMPHASIS-HF), its use in cirrhotic ascites as a spironolactone substitute for tolerability reasons is clinically accepted.

• Option B: Option B is incorrect: spironolactone's endocrine adverse effects in women are established and include breast tenderness (mastalgia), menstrual irregularities, and changes in libido — these occur through progesterone and androgen receptor cross-reactivity and are not exclusive to gynecomastia in men. The claim that women lack the relevant conversion pathway is pharmacologically incorrect.
• Option C: Option C is incorrect: furosemide-induced secondary hyperaldosteronism does not elevate estradiol through adrenal co-secretion; the adrenal zona glomerulosa secretes aldosterone in response to volume depletion, not estradiol. Secondary hyperaldosteronism does not cause breast tenderness or menstrual irregularities.
• Option D: Option D is incorrect: finerenone's primary evidence base is in diabetic CKD (FIDELIO-DKD, FIGARO-DKD), not cirrhotic ascites; it is not approved or guideline-endorsed for cirrhotic ascites management, making eplerenone — which has broader use in ascites as a class substitution — the better-supported choice in this setting.
• Option E: Option E is incorrect: amiloride blocks ENaC directly and can reduce sodium retention in ascites as an adjunct, but it does not provide equivalent efficacy to spironolactone for cirrhotic ascites as a standalone agent; in cirrhosis, the dominant sodium-retaining force is secondary hyperaldosteronism, and MR blockade by spironolactone or eplerenone is the pharmacological standard, not ENaC direct blockade.

ANSWER: E

Rationale:

This clinical picture is textbook acetazolamide-induced metabolic acidosis. The arterial blood gas (pH 7.28, HCO₃⁻ 14 mEq/L) with a compensatorily elevated chloride (hyperchloremic, non-anion-gap metabolic acidosis) is the expected pattern: acetazolamide inhibits proximal tubular carbonic anhydrase, forcing urinary sodium bicarbonate wasting. Over weeks of sustained therapy, the cumulative bicarbonate loss progressively lowers serum bicarbonate and pH. The clinical consequences of chronic metabolic acidosis include fatigue, anorexia, nausea, weight loss, and — at pH below 7.30 — cognitive impairment ranging from confusion to obtundation, which accounts for her daughter's observation that she seems "unlike herself." The hypokalemia (K⁺ 3.1 mEq/L) is also expected: as bicarbonate is wasted in the urine, it creates an obligate cation loss that includes potassium. The correct response is to discontinue systemic acetazolamide and transition her to a topical carbonic anhydrase inhibitor (dorzolamide or brinzolamide), which reduces aqueous humor production through local ciliary body CA inhibition without producing clinically significant systemic bicarbonate wasting or metabolic acidosis.

• Option A: Option A is incorrect: acetazolamide does not cause SIADH; it promotes urinary bicarbonate wasting, not free water retention. Her sodium is 138 mEq/L — genuinely normal, not relatively hypo-osmolar — and SIADH is not a recognized complication of carbonic anhydrase inhibition.
• Option B: Option B is incorrect: acetazolamide causes hypokalemia (through obligate kaliuresis accompanying bicarbonaturia), not hyperkalemia. Carbonic anhydrase inhibition in the collecting duct does not retain potassium through an electroneutral exchange mechanism; potassium handling in this setting is driven by distal tubular flow and the bicarbonaturia, which increases urinary potassium loss.
• Option C: Option C is incorrect: while acetazolamide is sulfonamide-derived and cross-reactivity is a valid concern at initiation, the presentation here is not consistent with an immune-mediated hypersensitivity reaction. The six-week symptom-free period followed by gradual metabolic deterioration with a predictable acid-base pattern is characteristic of cumulative pharmacodynamic toxicity, not a delayed allergic response.
• Option D: Option D is incorrect: acetazolamide does not cause nephrogenic diabetes insipidus; it does not block V2 receptors or prevent AQP2 insertion. The drug's primary action is in the proximal tubule, not the collecting duct principal cells where V2 receptors and AQP2 reside.

ANSWER: B

Rationale:

Acetazolamide is structurally derived from the sulfonamide scaffold and contains the sulfonamide functional group (-SO₂NH₂). While the pharmacological debate about cross-reactivity between sulfonamide antibiotics and non-antibiotic sulfonamide derivatives (including acetazolamide, furosemide, and thiazides) is nuanced — the N4-aromatic amine group implicated in immune-mediated reactions to sulfonamide antibiotics is absent in acetazolamide — clinical practice guidelines recommend avoiding acetazolamide in patients with documented sulfonamide allergy, particularly those with prior urticarial or severe reactions, because the risk of cross-reactivity is sufficient to justify substitution when a safe alternative exists. Dexamethasone is the established alternative for altitude sickness prophylaxis in sulfonamide-allergic individuals. It reduces altitude sickness symptoms through glucocorticoid-mediated reduction of cerebral and pulmonary edema formation and anti-inflammatory effects, typically dosed at 8 mg/day starting at or before ascent. Importantly, dexamethasone does not restore the hypoxic ventilatory response blunted by respiratory alkalosis at altitude — the mechanism by which acetazolamide works — and it must be tapered on descent rather than abruptly stopped. The locum's prescription should not be filled.

• Option A: Option A is incorrect: while the structural argument about the N4-aromatic amine is pharmacologically legitimate, clinical guidelines do not permit non-antibiotic sulfonamide use in patients with prior urticarial sulfonamide reactions on this basis alone; the urticarial severity and the availability of a safe alternative (dexamethasone) mandate substitution.
• Option C: Option C is incorrect: antihistamine premedication does not reliably prevent sulfonamide cross-reactivity reactions, particularly urticarial ones that have previously required emergency care; this approach is not guideline-supported for sulfonamide-allergic individuals requiring acetazolamide.
• Option D: Option D is incorrect: TMP-SMX allergy is most commonly attributed to the sulfamethoxazole (sulfonamide) component, not the trimethoprim component; the two drugs are structurally unrelated, and allergic reactions to TMP-SMX are typically sulfonamide-mediated. Dexamethasone is effective for altitude sickness prophylaxis at standard doses.
• Option E: Option E is incorrect: sulfonamide hypersensitivity is an immune-mediated reaction, not a dose-dependent pharmacodynamic effect; half-dosing does not reduce antigen presentation sufficiently to eliminate the cross-reactivity risk, and this approach has no evidence base in the management of sulfonamide-allergic patients.

ANSWER: D

Rationale:

This patient has exceeded the established mannitol osmolality safety threshold. The target serum osmolality for mannitol therapy is 310–320 mOsm/kg; above 320 mOsm/kg, two compounding problems develop. First, as plasma osmolality rises and brain tissue osmolality gradually equilibrates — particularly with repeated dosing over 72 hours — the osmotic gradient across the blood-brain barrier diminishes, reducing ICP-lowering efficacy and eventually risking paradoxical cerebral edema as equilibration progresses. Second, hyperosmolar states above 320 mOsm/kg produce renal tubular injury through hyperosmolar stress on proximal tubular cells — the oliguria (18 mL/hour from a baseline of 120 mL/hour) and rising creatinine (2.4 from 0.8 mg/dL) are consistent with mannitol-associated acute kidney injury and must be taken seriously in a patient who needs sustained ICP management. Mannitol must be discontinued. Hypertonic saline (3% NaCl) provides equivalent ICP reduction through the same principle — a hypertonic plasma-to-brain osmotic gradient drawing water out of brain parenchyma — but does not carry the same renal tubular toxicity threshold. It is titrated to serum sodium targets (typically 145–155 mEq/L) rather than osmolality targets, and can be continued safely when mannitol must be stopped.

• Option A: Option A is incorrect: escalating the mannitol dose when osmolality already exceeds 320 mOsm/kg and the patient has developing AKI would directly worsen both the renal toxicity and the diminishing osmotic gradient; this is the opposite of the correct response.
• Option B: Option B is incorrect: cessation of all osmotherapy when ICP remains at 31 mmHg is not appropriate — hypertonic saline is a viable and guideline-accepted alternative osmotic agent that can be transitioned to when mannitol is contraindicated; abandoning osmotherapy entirely risks fatal cerebral herniation.
• Option C: Option C is incorrect: furosemide does not synergize with mannitol by creating a free water diuresis that safely lowers serum osmolality; adding a loop diuretic to an already oliguric patient with AKI would worsen renal perfusion without meaningfully reducing the osmolar load, and this is not a recognized rescue strategy for mannitol-induced hyperosmolality.
• Option E: Option E is incorrect: the oliguria in this patient is not appropriate ADH-mediated water conservation — it is a sign of renal tubular injury from hyperosmolar stress; holding mannitol for 12 hours while waiting for the kidneys to lower osmolality is an inadequate response to documented AKI from a drug that must be discontinued.

ANSWER: A

Rationale:

Safe correction of chronic hyponatremia — regardless of treatment modality — must not exceed 8–10 mEq/L in any 24-hour period or 18 mEq/L in 48 hours, to prevent osmotic demyelination syndrome (ODS). ODS occurs because brain cells chronically adapted to hypo-osmolality by extruding organic osmolytes; if serum osmolality rises faster than these osmolytes can be restored, osmotic stress damages oligodendrocytes and disrupts myelin, particularly in the pons and extrapontine structures. At hour 14, this patient has already risen 11 mEq/L — exceeding the 24-hour limit — and tolvaptan's aquaretic effect will continue as long as the drug is present and being absorbed. The drug must be stopped immediately. Desmopressin (DDAVP) is the rescue agent: as a V2 receptor agonist, it restores cAMP-mediated AQP2 insertion in the collecting duct, reactivating water reabsorption and halting or reversing the free water excretion driving the sodium correction. Free water administration (oral water or hypotonic IV fluid) provides additional buffer. Critically, clinical improvement in cognition does not indicate the correction rate is safe — ODS risk depends on the rate and degree of osmolality change relative to brain adaptation, not on clinical symptoms during correction.

• Option B: Option B is incorrect: the 8–10 mEq/L limit is not a rolling average that permits 11 mEq/L at 14 hours as long as the subsequent 10 hours remain flat; tolvaptan's aquaretic effect cannot be reliably halted voluntarily at a target value, and the drug continues producing aquaresis. Once the limit is exceeded before 24 hours have elapsed, intervention is mandatory.
• Option C: Option C is incorrect: escalating tolvaptan at a rate that has already exceeded safe correction limits would dramatically worsen the overcorrection and substantially increase ODS risk; the improving cognition reflects resolution of hyponatremia encephalopathy, not a signal that faster correction is safe.
• Option D: Option D is incorrect: hypertonic saline raises serum sodium and plasma osmolality; administering it to a patient who is already overcorrecting would accelerate the sodium correction further, worsening the situation. Hypertonic saline is used to treat symptomatic hyponatremia, not to slow overcorrection.
• Option E: Option E is incorrect: tolvaptan does not have a sodium-sensitive negative feedback mechanism that reduces V2 receptor sensitivity as serum sodium rises; V2 receptor blockade by tolvaptan continues at the same pharmacological intensity as long as drug is present, and correction will continue without intervention.

ANSWER: C

Rationale:

This presentation is consistent with tolvaptan-associated drug-induced liver injury (DILI) — the clinical phenotype for which the FDA issued a boxed warning for the ADPKD indication. The boxed warning arose from the TEMPO 3:4 and subsequent ADPKD trials, which documented cases of serious and potentially fatal hepatocellular injury, including liver failure requiring transplantation. The characteristic pattern is hepatocellular injury (elevated ALT and AST disproportionate to alkaline phosphatase) appearing after months of continuous exposure — consistent with this patient at 8 months. The presence of clinical jaundice (scleral icterus, bilirubin 3.8 mg/dL) alongside significant transaminase elevations fulfills the criteria for drug-induced liver injury with jaundice (historically called "Hy's Law"), which identifies cases at high risk for progression to fulminant liver failure if the offending drug is continued. Tolvaptan must be discontinued immediately regardless of the viral hepatitis serology results, because the temporal relationship, duration of exposure, and clinical pattern are sufficient to mandate cessation. Hepatology evaluation is required to assess severity and monitor for progression of synthetic dysfunction.

• Option A: Option A is incorrect: polycystic liver disease cyst enlargement does not cause hepatocellular transaminase elevation with jaundice at this pattern; liver cysts produce mass effect and complications (bleeding, infection) but not hepatocellular DILI. Awaiting serologies before stopping tolvaptan in a patient with jaundice and ALT >7× upper limit of normal is clinically dangerous.
• Option B: Option B is incorrect: dose reduction to 15/5 mg is not an appropriate response to tolvaptan-associated hepatotoxicity with jaundice; the boxed warning indicates discontinuation, not dose adjustment, when liver injury is detected; and the premise that hepatotoxicity is always reversible with dose reduction is unsupported — cases of progressive liver failure after dose reduction have been documented.
• Option D: Option D is incorrect: tolvaptan's aquaretic effect produces dilute, colorless-to-pale urine — not dark urine. Dark urine in a patient with scleral icterus indicates conjugated hyperbilirubinemia from liver disease, not urinary concentration from V2 blockade. Hepatic congestion from mild volume depletion does not elevate ALT and AST to 7–8× the upper limit of normal.
• Option E: Option E is incorrect: N-acetylcysteine is not an established antidote or hepatoprotective agent for tolvaptan-associated DILI; there is no evidence that tolvaptan's hepatotoxicity involves glutathione depletion by reactive metabolites in a way that NAC would meaningfully address. Continuing tolvaptan while administering NAC is not appropriate management.

ANSWER: E

Rationale:

This question requires integrating the hemodynamic profiles of both vaptans with the clinical constraints of critical illness. Conivaptan blocks both V1a receptors (on vascular smooth muscle, mediating vasoconstriction) and V2 receptors. In a patient on norepinephrine 0.18 mcg/kg/min to maintain MAP in septic shock, any additional reduction in systemic vascular resistance from V1a blockade creates serious risk of refractory vasodilation and hemodynamic collapse — conivaptan is contraindicated. Tolvaptan is V2-selective and hemodynamically neutral, which eliminates the vasoconstriction concern; however, tolvaptan is an oral agent. In an ICU patient with septic shock, gastrointestinal absorption is profoundly impaired by splanchnic hypoperfusion, bowel edema, and frequently by intubation with sedation and reduced gastrointestinal motility — oral tolvaptan is unreliable and pharmacokinetically unpredictable in this setting. For acute symptomatic severe hyponatremia (sodium 121 mEq/L) in the vasopressor-dependent ICU, hypertonic saline (3% NaCl) administered IV is the correct agent: it corrects hyponatremia directly through sodium administration, is available as an IV formulation with predictable pharmacokinetics, does not depend on renal tubular aquaresis, and does not affect vascular tone.

• Option A: Option A is incorrect: conivaptan is explicitly contraindicated in hypotensive patients — its V1a blockade reduces systemic vascular resistance and worsens hypotension. The premise that V1a blockade is beneficial in septic shock by reducing "excessive vasopressin-mediated vasoconstriction" is dangerous clinical reasoning; in vasopressor-dependent septic shock, vasopressin's vasopressor contribution is protective, not harmful.
• Option B: Option B is incorrect: tolvaptan's V2 selectivity does make it hemodynamically neutral, which is an advantage over conivaptan; however, its oral formulation is not reliably absorbed in a critically ill ICU patient with septic shock and likely impaired gut absorption. Tolvaptan is not an appropriate first-line agent in this setting.
• Option C: Option C is incorrect: vasopressin's vasopressor effects in sepsis are mediated primarily by V1a receptors on vascular smooth muscle, not V1b receptors in the anterior pituitary; conivaptan's V1a blockade does reduce systemic vascular resistance at clinically used doses and is hemodynamically significant in vasopressor-dependent patients.
• Option D: Option D is incorrect: there is no established reduced-dose conivaptan regimen that selectively produces V2 aquaresis without clinically significant V1a vasodilation; the V1a and V2 blockade occur in parallel at all doses, and reducing the dose in a vasopressor-dependent patient does not reliably eliminate the hemodynamic risk.

ANSWER: B

Rationale:

Sequential nephron blockade with metolazone plus furosemide is one of the most potent diuretic combinations available, capable of generating urine outputs of 4–6 liters per day or more in responsive patients. This potency creates correspondingly high risk: rapid volume depletion causes pre-renal AKI through reduced renal perfusion pressure; massive urinary sodium and potassium losses (furosemide drives kaliuresis through increased distal sodium delivery, and the combined natriuresis dramatically amplifies total electrolyte loss) produce severe hypokalemia and hypomagnesemia; and the combination of hypotension, oliguria, and rising creatinine in this patient represents hemodynamic pre-renal AKI superimposed on her baseline CKD. The 4.2-liter first-day urine output was a signal that should have triggered urgent electrolyte reassessment — the mandatory protocol for this combination is electrolyte and renal function monitoring within 24–48 hours of initiation, precisely because the natriuretic effect can be dramatic and precipitous. Delaying the first check to 72 hours allowed severe electrolyte depletion and pre-renal AKI to develop unchecked. Immediate management: hold both diuretics, cautious IV fluid resuscitation (recognizing the risk of pulmonary edema in a patient with LVEF 22% — small boluses with close reassessment), and aggressive IV potassium and magnesium repletion.

• Option A: Option A is incorrect: furosemide ototoxicity occurs at very high doses or with rapid infusion and presents with tinnitus and hearing loss, not with creatinine elevation, hypokalemia, and hypotension; the creatinine rise here is pre-renal AKI from volume depletion, not cochlear injury. Increasing furosemide in a hypotensive oliguric patient is dangerous.
• Option C: Option C is incorrect: furosemide does not cause direct nephrotoxic ATN through OAT-mediated proximal tubular accumulation under normal clinical conditions; furosemide nephrotoxicity in isolation is rare and occurs only in extreme overdose or in the setting of aminoglycoside co-administration. The AKI here is hemodynamic (pre-renal), not tubular.
• Option D: Option D is incorrect: hypokalemia of 2.6 mEq/L and hypotension are not expected routine first-week responses to sequential blockade; they represent over-diuresis requiring intervention, not dose escalation. Increasing metolazone and adding spironolactone in a hypotensive oliguric patient would worsen the hemodynamic compromise and risk fatal arrhythmia from worsening hypokalemia.
• Option E: Option E is incorrect: the presentation is clearly over-diuresis, not inadequate diuresis. A 4.2-liter first-day output in a patient now hypotensive and oliguric is not rebound retention — it is the result of excessive fluid removal. The hypokalemia pattern (progressive urinary potassium loss from loop + NCC blockade) is mechanistically distinct from hyperaldosteronism-driven kaliuresis, which would occur in the setting of volume overload, not volume depletion.

ANSWER: D

Rationale:

This question requires applying the mechanistic distinction between MR-dependent and aldosterone-independent potassium-sparing strategies to a patient with a defined low-aldosterone state. Type IV RTA (hyporeninemic hypoaldosteronism) is characterized by impaired renin secretion — typically from diabetic nephropathy-related juxtaglomerular apparatus dysfunction — leading to low angiotensin II, low aldosterone, impaired collecting duct potassium secretion, and a hyperchloremic non-anion-gap metabolic acidosis with hyperkalemia. The baseline potassium of 5.4 mEq/L reflects this impaired potassium excretion capacity. HCTZ has reduced his potassium to 3.6 mEq/L through kaliuresis — now a potassium-sparing agent is needed. Spironolactone competitively blocks the MR by displacing aldosterone; in a patient with negligible circulating aldosterone, there is essentially no aldosterone to displace, and MR occupancy by spironolactone produces minimal incremental suppression of ENaC and ROMK beyond the already-suppressed baseline. Amiloride blocks ENaC directly, providing potassium-sparing effect independently of the aldosterone axis. The critical caveat is dose and monitoring: this patient's underlying type IV RTA already limits his ability to excrete potassium; amiloride's added ENaC blockade risks restoring or worsening hyperkalemia. Low-dose amiloride with frequent potassium monitoring is the correct approach.

• Option A: Option A is incorrect: type IV RTA involves aldosterone deficiency (low aldosterone), not aldosterone resistance; the MR is functional but understimulated. Spironolactone cannot overcome the absence of aldosterone by achieving higher MR occupancy.
• Option B: Option B is incorrect: spironolactone corrects metabolic alkalosis from excess aldosterone (e.g., primary hyperaldosteronism), not the metabolic acidosis of type IV RTA where low aldosterone is the cause; blocking an already-low aldosterone signal worsens rather than corrects the acidosis by further reducing H⁺ secretion in intercalated cells.
• Option C: Option C is incorrect: the potassium drop from 5.4 to 3.6 mEq/L with HCTZ reflects thiazide-induced kaliuresis, which occurs through increased distal sodium delivery and enhanced ROMK-mediated potassium secretion driven by increased tubular flow — this does not exclude hyporeninemic hypoaldosteronism; the baseline hyperkalemia before HCTZ is consistent with impaired potassium excretion capacity that is now being partially overcome by pharmacologically driven tubular flow.
• Option E: Option E is incorrect: spironolactone does not correct the tubular acidification defect of type IV RTA through MR blockade of "aberrant aldosterone signaling"; type IV RTA involves insufficient aldosterone action (not excess), and blocking the already-low aldosterone signal further impairs acid secretion and potassium excretion.

ANSWER: A

Rationale:

The mechanistic chain connecting metabolic alkalosis to loop diuretic resistance and acetazolamide's reversal of it is clinically and pharmacologically precise. Furosemide-driven volume contraction stimulates the RAAS, raising angiotensin II, which upregulates NHE3 (the apical sodium-hydrogen exchanger isoform 3) in the proximal convoluted tubule. Metabolic alkalosis — driven by volume contraction, hypokalemia shifting H⁺ intracellularly, and secondary hyperaldosteronism increasing intercalated cell proton secretion — further enhances NHE3 activity because the bicarbonate-rich, angiotensin II-stimulated environment promotes sodium and bicarbonate reabsorption in the PCT. The result: less sodium reaches the loop of Henle, reducing the substrate available for NKCC2 blockade by furosemide, and the natriuretic effect per dose diminishes. Acetazolamide breaks this cycle by inhibiting luminal CA IV and intracellular CA II in the PCT, preventing H⁺ regeneration for NHE3, and forcing urinary bicarbonate wasting. Correcting the alkalosis normalizes angiotensin II-driven NHE3 upregulation, restores sodium delivery to the loop, and simultaneously provides additional proximal natriuresis through the bicarbonaturia itself. The ADVOR trial (Mullens et al., NEJM 2022) randomized 519 hospitalized decompensated heart failure patients to acetazolamide 500 mg IV daily versus placebo, both on top of standardized IV loop diuretic therapy; the acetazolamide group had significantly higher rates of successful decongestion (defined as no signs of volume overload) at 3 days — 42.2% vs 30.5%, p=0.001.

• Option B: Option B is incorrect: furosemide acts from the luminal side of NKCC2 after secretion into the proximal tubular lumen via OAT transporters; its tubular action is not governed by ionization state in the tubular fluid in the way described, and alkaline urinary pH does not trap furosemide in a charged form preventing NKCC2 access. The ADVOR trial did not show an eGFR improvement as its primary endpoint.
• Option C: Option C is incorrect: OAT1-mediated furosemide secretion is not inhibited by alkaline pH through conformational changes in the transporter; this mechanism is fabricated. The ADVOR trial did not demonstrate reduced in-hospital mortality — its primary endpoint was successful decongestion at 3 days.
• Option D: Option D is incorrect: metabolic alkalosis does not trigger ADH hypersecretion from the hypothalamus through pH sensing; ADH secretion in heart failure is driven by non-osmotic stimuli (reduced cardiac output, baroreceptor activation), not by alkalemia. The ADVOR trial did not evaluate vaptan use reduction as an endpoint.
• Option E: Option E is incorrect: furosemide is primarily renally eliminated as unchanged drug (hepatic metabolism is minor), and acetazolamide has no CYP3A4 inhibitory activity; carbonic anhydrase inhibition does not interfere with cytochrome P450 electron transport. The ADVOR trial did not measure furosemide half-life.